Acetaminophen / hydrocodone Alternatives Compared
Acetaminophen / hydrocodone | Xeljanz (tofacitinib) | Methotrexate |
|
---|
Acetaminophen / hydrocodone | Xeljanz (tofacitinib) | Methotrexate |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Acetaminophen/hydrocodone may be used to treat moderate-to-severe pain that is unrelieved by nonopioid analgesics. However, its use is limited by the dependence and addiction potential of the... View more |
Prescription only
Xeljanz is a Janus kinase (JAK) inhibitor that may be used to reduce inflammation associated with several conditions such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, or... View more |
Prescription only
Methotrexate may be considered for the treatment of psoriasis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (pJIA), mycosis fungoides, and certain cancers, such as ALL or... View more |
Related suggestions Rheumatoid Arthritis
|
|||||||||||||||||||||||
More about Acetaminophen / hydrocodone | More about Xeljanz (tofacitinib) | More about Methotrexate | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Acetaminophen / hydrocodone has an average rating of 6.0 out of 10 from a total of 1315 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 35% reported a negative effect. |
Xeljanz has an average rating of 5.7 out of 10 from a total of 145 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 40% reported a negative effect. |
Methotrexate has an average rating of 6.5 out of 10 from a total of 335 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 24% reported a negative effect. |
||||||||||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Xeljanz side effects |
View all Methotrexate side effects |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
Lower cost generic |
|||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Acetaminophen / hydrocodone prices |
View all Xeljanz prices |
View all Methotrexate prices |
||||||||||||||||||||||||
Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Xodol, Zyfrel | Other tofacitinib brands include: Xeljanz Oral Solution, Xeljanz XR | Jylamvo, Methotrexate LPF Sodium, Otrexup, Rasuvo, Trexall, Xatmep | ||||||||||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
3.8 hours |
3 hours |
15 hours |
||||||||||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
High potential for abuse
Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 679 drugs are known to interact with Acetaminophen / hydrocodone:
|
A total of 655 drugs are known to interact with Xeljanz:
|
A total of 716 drugs are known to interact with Methotrexate:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
May 03, 1982 |
November 06, 2012 |
December 07, 1953 |
||||||||||||||||||||||||
WADA Class View classifications | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient Resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
|
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.